Live Breaking News & Updates on மூளை காயம் ப்ரோக்ர்யாம்

Share this article
Share this article
ATLANTA, May 11, 2021 /PRNewswire/  NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of acquired brain injury, today announced it has entered into a research collaboration with Antwerp University Hospital, Belgium, to help support Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI), a prospective longitudinal observational study that is collecting clinical and epidemiological data to identify the most effective clinical care and treatment recommendations, develop and validate surrogate biomarkers of injury and recovery, and improve the classification of traumatic brain injury (TBI) to enable targeted therapies. ....

United States , United Kingdom , John Claude Saltiel , Carl Long , Susan Pietropaolo , Davidk Menon , Centers For Disease , Us Department Of Defense , European Commission , Brain Injury Program , Neurotrauma Sciences , University Of Cambridge , Wolfson Brain Imaging Centre , International Initiative For Traumatic Brain Injury Research , Corporate Development , Us National Institutes Of Health , Chief Executive Officer , Trauma Science , Principal Investigator , Acute Brain Injury Program , Addenbrookes Hospital , Disease Control , Traumatic Brain Injury , International Initiative , Traumatic Brain Injury Research , Trauma Sciences ,